8-K: Tarsus Pharmaceuticals Reports Strong Q1 2025 Results Driven by XDEMVY Sales

Tarsus Pharmaceuticals announces a successful first quarter in 2025, highlighted by a 217% year-over-year increase in XDEMVY net product sales and a strengthened financial position following a public equity offering.

Summary

• Tarsus Pharmaceuticals reported its financial results for the first quarter ended March 31, 2025.
• Net product sales of XDEMVY reached $78.3 million, a 217% increase year-over-year and an 18% increase compared to Q4 2024.
• Approximately 72,000 bottles of XDEMVY were dispensed to patients during the quarter, a 23% increase over Q4 2024.
• The company's financial position was strengthened by a $134.8 million public equity offering.
• As of March 31, 2025, cash, cash equivalents, and marketable securities totaled approximately $408 million.
• Tarsus is on track to initiate a Phase 2 trial of TP-04 for Ocular Rosacea in the second half of 2025.
• The company anticipates meeting with regulatory authorities in Japan in H2 2025 to determine a regulatory path forward for XDEMVY in Japan.
• Tarsus is on track for potential European regulatory approval in 2027 of a preservative-free formulation of XDEMVY.
• A Phase 2 study of TP-05 for the potential prevention of Lyme disease is expected to begin in 2026.
• The net loss for the quarter was $25.1 million, compared to $35.7 million for the same period in 2024.
• Basic and diluted net loss per share for the quarter ended March 31, 2025 was $(0.64), compared with $(1.01) for the same period in 2024.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong sales growth, successful capital raising, and advancement of the pipeline. While there are risks and ongoing losses, the overall tone is optimistic and suggests a promising future for the company.

Positives

• Significant increase in XDEMVY sales indicates strong market adoption and demand.
• The successful equity offering strengthens the company's financial position, providing resources for further growth and development.
• Advancement of the pipeline with multiple catalysts expected in 2025 demonstrates commitment to innovation.
• Increase in ECP prescriptions and website visits suggests effective marketing and outreach strategies.
• Reduction in net loss compared to the same period in 2024 indicates improved operational efficiency.

Negatives

• Selling, general and administrative (SG&A) expenses increased significantly, primarily due to increased commercial and marketing costs.
• The company is still operating at a net loss, although the loss has decreased compared to the previous year.
• Gross-to-net discount of approximately 47% indicates significant rebates and discounts are being offered, impacting net revenue.

Risks

• Tarsus is heavily dependent on the successful commercialization of XDEMVY.
• The company's capital requirements are difficult to predict and may change.
• Tarsus may need to obtain additional funding to achieve its goals.
• The sizes of the market opportunity for XDEMVY and Tarsus' product candidates have not been established with precision and may be smaller than estimated.
• The results of Tarsus' earlier studies and trials may not be predictive of future results.
• Tarsus is dependent on intellectual property it licenses from Elanco Tiergesundheit AG.

Future Outlook

Tarsus anticipates continued growth of XDEMVY, advancement of its pipeline, and potential regulatory approvals in Europe and Japan. The company expects to continue investing in its business to drive long-term growth.

Management Comments

• The XDEMVY launch is continuing to exceed our expectations and is on track to potentially become one of the best-selling anterior segment medicines, said Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus.
• Building on a foundation of strong commercial performance and the success of our recent equity offering, we believe we are well positioned to accelerate the growth of XDEMVY, create another new category in Ocular Rosacea and continue to advance our pipeline.

Industry Context

Tarsus is operating in the eye care market, specifically targeting Demodex blepharitis and Ocular Rosacea. The company's focus on addressing unmet needs in these areas positions it to potentially capture significant market share. The success of XDEMVY could establish Tarsus as a leader in anterior segment medicines.

Comparison to Industry Standards

• Comparing Tarsus's XDEMVY launch to other anterior segment medications like Xiidra (Novartis) and Restasis (Allergan/AbbVie), the growth trajectory appears promising.
• Xiidra achieved peak sales of approximately $400 million annually, while Restasis reached over $1 billion before generic competition.
• If XDEMVY continues its current growth rate, it could potentially reach similar peak sales levels, establishing it as a leading product in the category.
• Other companies in the eye care space, such as Kala Pharmaceuticals and Ocular Therapeutix, focus on different aspects of eye health, but Tarsus's specific focus on Demodex blepharitis provides a unique market niche.

Stakeholder Impact

• Shareholders benefit from the increased revenue and strengthened financial position.
• Employees may see increased job security and opportunities for advancement.
• Customers gain access to a potentially effective treatment for Demodex blepharitis.
• Suppliers may experience increased demand for their products and services.
• Creditors benefit from the company's improved financial stability.

Next Steps

• Initiate Phase 2 trial of TP-04 for Ocular Rosacea in H2 2025.
• Meet with regulatory authorities in Japan in H2 2025 to determine a regulatory path forward for XDEMVY.
• Continue advancing the pipeline with multiple catalysts expected in 2025.
• Initiate a Phase 2 study of TP-05 for the potential prevention of Lyme disease in 2026.
• Pursue potential European regulatory approval in 2027 of a preservative-free formulation of XDEMVY.

Key Dates

Keywords

XDEMVY, Tarsus Pharmaceuticals, Ocular Rosacea, Demodex Blepharitis, TP-04, TP-05, Lotilaner, Financial Results, Equity Offering, Eye Care